Company: ANTX
Filing Date: 2025-04-10
Form Type: DEF 14A
Source: 0000950170-25-052852
Chunk: 11

Company: AN2 Therapeutics, Inc.
Filing Date: 2025-04-10
Form: DEF 14A
Chunk 11
---
 Executive Officer and Board Chair 
 Class III Director                                 |     |  57 |
| Stephanie Wong (1)(3)        | ﻿ | Class III Director                                 |     |  51 |
| Joseph Zakrzewski (1)(3)     |   | Class III Director                                 |     |  62 |
| Continuing Directors:        | ﻿ |                                                    |     |     |
| Kabeer Aziz (3)              | ﻿ | Class I Director                                   |     |  35 |
| Gilbert Lynn Marks, M.D. (2) | ﻿ | Class I Director                                   |     |  67 |
| Rob Readnour, Ph.D. (1)      | ﻿ | Class I Director                                   |     |  61 |
| Margaret FitzPatrick (1)(4)  | ﻿ | Class II Director                                  |     |  59 |
| Patricia Martin (2)          | ﻿ | Class II Director                                  |     |  64 |
| Melvin Spigelman, M.D. (2)   |   | Class II Director                                  |     |  76 |

(1) Member of the nominating and corporate governance committee. (2) Member of the compensation committee. (3) Member of the audit committee. (4) Lead independent director. Nominees for Election to a Three-Year Term Ending at the 2028 Annual Meeting Eric Easom is a co-founder of our Company and has served as our President and Chief Executive Officer and a member of our Board since November 2019, and Board chair since June 2024. From February 2009 to June 2017, Mr. Easom served as Vice President, Neglected Diseases at Anacor Pharmaceuticals, Inc. (“Anacor”), a publicly traded biopharmaceutical company that was acquired by Pfizer Inc. From July 2007 to January 2009, Mr. Easom served as the Senior Director, Business Development and Marketing at InteKrin Therapeutics, Inc., a biopharmaceutical company. From April 2006 to July 2007, he served as the Director of Marketing at MedImmune, a biotechnology company that was acquired by AstraZeneca. Mr. Easom currently serves as a member of the board of directors of the Chagas Disease Foundation and Resilient Biotics, Inc., a private microbiome-based therapeutics company, and is an advisor for the California Life Sciences Institute. Mr. Eas